Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MediClin AGXTER:MED 75 3-1 Month Momentum % is 3.81% as of Sep. 06, 2026. GuruFocus rates XTER:MED with a GF Score™ of 75/100 and a GF Value™ of €3.21 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 665 Healthcare Providers & Services companies, MediClin AG ranks better than 59.7% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-09-06), MediClin AG's 3-1 Month Momentum % is 3.81%.
The industry rank for MediClin AG's 3-1 Month Momentum % or its related term are showing as below:
XTER:MED's 3-1 Month Momentum % is ranked better than 59.7% of 665
companies
in the Healthcare Providers & Services industry
Industry Median: -0.47
vs XTER:MED: 3.81
MediClin AG (XTER:MED) 3-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
MediClin AG 3-1 Month Momentum % Related Terms
XTER:MED vs HCA, THC, EHC: 3-1 Month Momentum % Comparison
For the Medical Care Facilities subindustry, MediClin AG's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MediClin AG 3-1 Month Momentum % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, MediClin AG's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where MediClin AG's 3-1 Month Momentum % falls into.
MediClin AG (XTER:MED) 3-1 Month Momentum % Calculation
3-1 Month Momentum % is calculated as following:
3-1 Month Momentum %
=
( Price 1-month ago
/
Price 3-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MediClin AG (XTER:MED) has a 3-1 Month Momentum % of 3.81% as of Sep. 06, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on MediClin AG and its competitors. According to the industry distribution chart, MediClin AG ranks #268 out of 665 companies in the Healthcare Providers & Services industry, placing it in the top 40.3%.
Is MediClin AG's 3-1 Month Momentum % too high?
MediClin AG's current 3-1 Month Momentum % is 3.81%. Based on the distribution chart, MediClin AG ranks #268 out of 665 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, MediClin AG has a GF Score™ of 75/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does MediClin AG's 3-1 Month Momentum % compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, MediClin AG ranks #268 out of 665 companies for 3-1 Month Momentum %. This puts MediClin AG in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Healthcare Providers & Services company?
A good 3-1 Month Momentum % depends on the Healthcare Providers & Services industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on MediClin AG and its competitors. MediClin AG's current 3-1 Month Momentum % is 3.81%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MediClin AG stock overvalued right now?
Based on GuruFocus' analysis, MediClin AG (XTER:MED) is currently considered Significantly Overvalued. The stock's GF Value™ is €3.21, compared to a current price of €5.50 — trading 71.3% above its estimated fair value. The current 3-1 Month Momentum % is 3.81%. MediClin AG's overall GF Score™ is 75/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For MediClin AG (XTER:MED), the current 3-1 Month Momentum % is 3.81% as of Sep. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MediClin AG (XTER:MED) Overvalued in 2026?
Based on GuruFocus' analysis, MediClin AG stock appears to be overvalued.
The current stock price of €5.50 is trading 71.3% above its estimated GF Value™ of €3.21.
GuruFocus considers MediClin AG to be Significantly Overvalued.
Key valuation signals for XTER:MED:
3-1 Month Momentum %: 3.81%
GF Value™: €3.21 vs. price of €5.50 (71.3% above fair value)
No single metric tells the full story. See the XTER:MED stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MediClin AG operates hospitals and other medical care centers. The company's reportable operating segments are the Post-acute, Acute, Nursing care, and Service segments. A majority of its revenue is generated from the Post-acute segment, which offers services in the fields of follow-up rehabilitation treatment and curative treatment. Some of the post-acute hospitals also offer services in acute neurology and acute psychosomatics. The Acute segment encompasses medical offerings with a focus on neurology and neurological early rehabilitation as well as psychosomatic medicine, psychiatry, orthopaedics, and internal medicine. The Nursing care segment offers full-time and part-time nursing care as well as daycare, and the Service segment consists of the central services.
75GF Score
Get the complete analysis for XTER:MED
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTER:MED has been successfully added to your 
